← Back to Search

Radiation Therapy

Stereotactic Ablative Radiotherapy for Liver Cancer

N/A
Waitlist Available
Led By Roy Ma, MD
Research Sponsored by British Columbia Cancer Agency
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up to be reviewed in approximately 8 years; upon study completion
Awards & highlights

Study Summary

Respiratory-gated, volumetric-modulated arc therapy will be used for the clinical development of high dose rate Stereotactic Body Radiotherapy (SBRT) in inoperable hepatocellular carcinoma (HCC). These treatments should enhance local control, progression-free survival and potentially overall survival in HCC patients. The investigators will also examine the mechanism of tumour and microenvironmental response to high dose radiation, and search for potential biomarkers to optimize and individualize therapy. Pre-treatment and follow-up PET/CT imaging with 11C-choline, 18F-fluorodeoxyglucose (FDG) and CT perfusion will examine in-vivo changes in proliferation, glycolysis, and the tumour vasculature, respectively, and blood samples will look for immunologic biomarkers of tumour response.

Eligible Conditions
  • Liver Cancer

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~to be reviewed in approximately 8 years; upon study completion
This trial's timeline: 3 weeks for screening, Varies for treatment, and to be reviewed in approximately 8 years; upon study completion for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
One year local progression-free rate
Secondary outcome measures
Cytokine response to radiation and association with complications
Functional imaging with 11C-choline/18F-FDG CT-PET and perfusion CT to that characterize treatment-related effects
Overall Survival
+3 more

Trial Design

1Treatment groups
Experimental Treatment
Group I: Stereotactic Ablative RadiotherapyExperimental Treatment1 Intervention
Preferred target coverage of 40 Gy: coverage and total dose determined by irradiated liver volume NTCP (normal tissue complication probability) nomogram and OAR dose limits

Find a Location

Who is running the clinical trial?

British Columbia Cancer AgencyLead Sponsor
171 Previous Clinical Trials
90,498 Total Patients Enrolled
Roy Ma, MDPrincipal InvestigatorBritish Columbia Cancer Agency

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
clinicaltrials.govStudy
Hepatocellular Carcinoma Using Stereotactic Body Radiotherapy
2013. "Hepatocellular Carcinoma Using Stereotactic Body Radiotherapy". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT01850316.
All > Hcc > Hepatocellular Carcinoma
~1 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top